Repository logo
 
Publication

Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study

2024-04-23Journal article Open access
Simple item page
dc.contributor.authorMonge, Susana
dc.contributor.authorHumphreys, James
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorBraeye, Toon
dc.contributor.authorVan Evercooren, Izaak
dc.contributor.authorHolm Hansen, Christian
dc.contributor.authorEmborg, Hanne‐Dorthe
dc.contributor.authorSacco, Chiara
dc.contributor.authorMateo‐Urdiales, Alberto
dc.contributor.authorCastilla, Jesús
dc.contributor.authorMartínez‐Baz, Iván
dc.contributor.authorde Gier, Brechje
dc.contributor.authorHahné, Susan
dc.contributor.authorMeijerink, Hinta
dc.contributor.authorKristoffersen, Anja Bråthen
dc.contributor.authorMachado, Ausenda
dc.contributor.authorSoares, Patricia
dc.contributor.authorNardone, Anthony
dc.contributor.authorBacci, Sabrina
dc.contributor.authorKissling, Esther
dc.contributor.authorNunes, Baltazar
dc.date.accessioned2025-03-05T15:24:15Z
dc.date.available2025-03-05T15:24:15Z
dc.date.issued2024-04-23
dc.description.abstractUsing a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65- to 79-year-olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.pt_PT
dc.description.sponsorshipEuropean Centre for Disease Prevention and Control (ECDC) implementing Framework Contract ECDC/2021/018 ‘Vaccine effectiveness and impact of COVID-19 vaccines through routinely collected exposure and outcome using health registries’ (RS/2022/DTS/24104). In Portugal, this work was also supported by FCT – Fundação para a Ciência e Tecnologia, I.P. by project reference CEECINST/00049/2021/CP2817/CT0001 and DOI identifier 10.54499/CEECINST/00049/2021/CP2817/CT0001.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationInfluenza Other Respir Viruses. 2024 Apr;18(4):e13292. doi: 10.1111/irv.13292.
dc.identifier.doi10.1111/irv.13292pt_PT
dc.identifier.issn1750-2640
dc.identifier.pmid38654485
dc.identifier.urihttp://hdl.handle.net/10400.18/10409
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWiley-VCH Verlag
dc.relationNot Available
dc.relation.hasversionhttps://onlinelibrary.wiley.com/doi/10.1111/irv.13292
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1111/irv.13292pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCOVID-19
dc.subjectSARS‐CoV‐2
dc.subjectCohort Design
dc.subjectElectronic Health Records
dc.subjectVaccine Effectiveness
dc.subjectHospitalisation
dc.subjectMulticountry Study
dc.subjectVEBIS-Lot 4pt_PT
dc.subjectEurope
dc.subjectVacina COVID-19pt_PT
dc.subjectEfetividadept_PT
dc.subjectRegistos Eletrónicos em Saúdept_PT
dc.subjectCuidados de Saúdept_PT
dc.subjectInfecções Respiratórias
dc.titleEffectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Studypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleNot Available
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/CEEC INST 2ed/CEECINST%2F00049%2F2021%2FCP2817%2FCT0001/PT
oaire.citation.issue4pt_PT
oaire.citation.startPagee13292
oaire.citation.titleInfluenza and Other Respiratory Viruses
oaire.citation.volume18pt_PT
oaire.fundingStreamCEEC INST 2ed
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameMachado
person.familyNameSoares
person.givenNameAusenda
person.givenNamePatricia
person.identifier1050496
person.identifier.ciencia-id1217-6076-5D88
person.identifier.ciencia-id0415-632D-8609
person.identifier.orcid0000-0002-1849-1499
person.identifier.orcid0000-0001-5033-9115
person.identifier.scopus-author-id52063758300
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublicationdf1b8bab-1e35-4561-92d0-8aeb17371a29
relation.isAuthorOfPublication.latestForDiscovery544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isProjectOfPublicationc9036720-2967-4a03-bb00-9daeafe5c02c
relation.isProjectOfPublication.latestForDiscoveryc9036720-2967-4a03-bb00-9daeafe5c02c

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Influenza Resp Viruses - 2024 - Monge - Effectiveness of XBB 1 5 Monovalent COVID‐19 Vaccines During a Period of XBB 1 5.pdf
Size:
1.39 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Artigos em revistas internacionais
DDI - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais